PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-Treatment Patients With Chronic Hepatitis C: An Open-Label Control Study in China.

Abstract Hepatitis B vaccine is an effective measure to prevent hepatitis B virus infection. Whether chronic hepatitis C virus (HCV) infection decreases humoral and cell-mediated immunity responses to hepatitis B vaccination is still controversial.
PMID
Related Publications

Anti-HBs persistence after revaccination with three doses of hepatitis B vaccines among non-responsive adults: 24-month of follow-up.

Anti-HBs persistence following primary vaccination with three doses of hepatitis B vaccine among normal and high-responder adults: a 3-year follow-up study.

A Longitudinal Hepatitis B Vaccine Cohort Demonstrates Long-lasting Hepatitis B Virus (HBV) Cellular Immunity Despite Loss of Antibody Against HBV Surface Antigen.

Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine.

Surface antibody and cytokine response to recombinant Chinese hamster ovary cell (CHO) hepatitis B vaccine.

Authors

Mayor MeshTerms
Keywords

anti-HBs

cell-mediated immunity

chronic hepatitis C

hepatitis B vaccine

Journal Title the journal of infectious diseases
Publication Year Start




PMID- 28859430
OWN - NLM
STAT- MEDLINE
DA  - 20170901
DCOM- 20170907
LR  - 20170907
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
VI  - 216
IP  - 3
DP  - 2017 Aug 01
TI  - Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among
      Not-in-Treatment Patients With Chronic Hepatitis C: An Open-Label Control Study
      in China.
PG  - 327-335
LID - 10.1093/infdis/jix295 [doi]
AB  - Background: Hepatitis B vaccine is an effective measure to prevent hepatitis B
      virus infection. Whether chronic hepatitis C virus (HCV) infection decreases
      humoral and cell-mediated immunity responses to hepatitis B vaccination is still 
      controversial. Methods: Patients with chronic HCV infection who were not in
      treatment and healthy controls, matched at a 1:2 ratio for community, sex, and
      age (within 5 years), were identified from a community-based screening. All
      participants received 3 doses of hepatitis B vaccine. Antibody to hepatitis B
      surface antigen was tested 1 month after the third vaccine dose and was compared 
      between 2 groups. Spot-forming cells (SFCs) of interferon gamma and interleukin
      2, 4, 5, and 6 were counted by means of enzyme-linked immunospot, and SFC counts 
      were compared between the 2 groups. Results: The rates of nonresponse and low,
      normal, and high response were 3.80%, 10.13%, 45.57%, and 40.50% respectively, in
      the HCV group, and the corresponding rates in the healthy control group were
      1.26%, 10.13%, 39.24%, and 49.37% (all P > .05). There were no significant
      differences in SFC counts between the 2 groups for interferon gamma or
      interleukin 2, 4, or 5 (all P > .05). Conclusions: This study provided
      preliminary evidence of the good immunogenicity and safety of hepatitis B
      vaccination among patients in China with chronic hepatitis C who are not in
      treatment. Clinical Trials Registration: NCT 02898922.
FAU - Liu, Jiaye
AU  - Liu J
AD  - Academy of Preventive Medicine, Shandong University.
AD  - Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention, 
      Shandong Provincial Center for Disease Control and Prevention, Jinan.
FAU - Qiu, Shaohui
AU  - Qiu S
AD  - National Institutes for Food and Drug Control.
FAU - Lu, Jingjing
AU  - Lu J
AD  - Academy of Preventive Medicine, Shandong University.
AD  - Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention, 
      Shandong Provincial Center for Disease Control and Prevention, Jinan.
FAU - Yan, Bingyu
AU  - Yan B
AD  - Academy of Preventive Medicine, Shandong University.
AD  - Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention, 
      Shandong Provincial Center for Disease Control and Prevention, Jinan.
FAU - Feng, Yi
AU  - Feng Y
AD  - Academy of Preventive Medicine, Shandong University.
AD  - Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention, 
      Shandong Provincial Center for Disease Control and Prevention, Jinan.
FAU - Li, Li
AU  - Li L
AD  - Chinese Center for Disease Control and Prevention, Beijing.
FAU - Zhang, Guomin
AU  - Zhang G
AD  - Chinese Center for Disease Control and Prevention, Beijing.
FAU - Wang, Fuzhen
AU  - Wang F
AD  - Chinese Center for Disease Control and Prevention, Beijing.
FAU - He, Peng
AU  - He P
AD  - National Institutes for Food and Drug Control.
FAU - Fang, Xin
AU  - Fang X
AD  - National Institutes for Food and Drug Control.
FAU - Hu, Zhongyu
AU  - Hu Z
AD  - National Institutes for Food and Drug Control.
FAU - Liang, Xiaofeng
AU  - Liang X
AD  - Chinese Center for Disease Control and Prevention, Beijing.
FAU - Xu, Aiqiang
AU  - Xu A
AD  - Academy of Preventive Medicine, Shandong University.
AD  - Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention, 
      Shandong Provincial Center for Disease Control and Prevention, Jinan.
FAU - Zhang, Li
AU  - Zhang L
AD  - Academy of Preventive Medicine, Shandong University.
AD  - Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention, 
      Shandong Provincial Center for Disease Control and Prevention, Jinan.
LA  - eng
PT  - Clinical Trial, Phase IV
PT  - Journal Article
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (Cytokines)
RN  - 0 (Hepatitis B Antibodies)
RN  - 0 (Hepatitis B Surface Antigens)
RN  - 0 (Hepatitis B Vaccines)
SB  - AIM
SB  - IM
MH  - Adult
MH  - Case-Control Studies
MH  - China
MH  - Cytokines/blood
MH  - Female
MH  - Hepatitis B/*prevention & control
MH  - Hepatitis B Antibodies/*blood
MH  - Hepatitis B Surface Antigens/immunology
MH  - Hepatitis B Vaccines/*administration & dosage/therapeutic use
MH  - Hepatitis C, Chronic/*immunology
MH  - Humans
MH  - Immunity, Cellular
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Surveys and Questionnaires
MH  - Young Adult
OTO - NOTNLM
OT  - anti-HBs
OT  - cell-mediated immunity
OT  - chronic hepatitis C
OT  - hepatitis B vaccine
EDAT- 2017/09/02 06:00
MHDA- 2017/09/08 06:00
CRDT- 2017/09/02 06:00
PHST- 2016/09/20 [received]
PHST- 2017/06/21 [accepted]
AID - 3882684 [pii]
AID - 10.1093/infdis/jix295 [doi]
PST - ppublish
SO  - J Infect Dis. 2017 Aug 1;216(3):327-335. doi: 10.1093/infdis/jix295.